ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.530 +0.030 (+0.55%)

Streaming Delayed Price Updated: 1:45 PM EDT, Aug 21, 2026 Add to My Watchlist

Price and Volume

Volume	514,189
Open	5.520
Bid (Size)	5.520 (500)
Ask (Size)	5.530 (3,900)
Prev. Close	5.500
Today's Range	5.465 - 5.600
52wk Range	4.910 - 15.09
Shares Outstanding	95,568,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Today 10:24 EDT

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

Today 10:00 EDT

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-51.9%	-51.9%
1 Month	-13.1%	-13.1%
3 Month	-32.8%	-32.8%
6 Month	-41.4%	-41.4%
1 Year	-62.1%	-62.1%

More News

ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Via The Motley Fool

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

August 20, 2026

Via NewMediaWire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

August 18, 2026

From Pomerantz LLP

Via GlobeNewswire

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026

August 18, 2026

Via NewMediaWire

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

August 18, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on

August 18, 2026

From Grabar Law Office

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

August 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

August 16, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

August 15, 2026

From Pomerantz LLP

Via GlobeNewswire

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

August 14, 2026

From Grabar Law Office

Via GlobeNewswire

ARS Pharmaceuticals Q2 Earnings Call Highlights ↗

August 13, 2026

Via MarketBeat

Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

August 13, 2026

Via NewMediaWire

ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 13, 2026

Via Benzinga

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

August 13, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

August 13, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY

August 13, 2026

Via Newsfile

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

August 11, 2026

From Pomerantz LLP

Via GlobeNewswire

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

August 11, 2026

Via NewMediaWire

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

August 11, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY

August 10, 2026

From DJS LAW GROUP

Via Business Wire

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

August 08, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

August 07, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

August 06, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?

ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market

What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?

The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.530

When was ARS Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/21/26 01:45 PM ET

What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?

The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 528.49M

How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?

ARS Pharmaceuticals, Inc. - Common Stock has 528M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.